deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT02174419

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

A Randomized, Double-Blind, Placebo-Controlled, Parallel, 3-Arm Study of the Safety and Anti-Pruritic Efficacy of Nalbuphine HCl ER Tablets in Prurigo Nodularis Patients

Sponsor: Trevi Therapeutics

Conditions Nodularis Prurigo Prurigo Prurigo Nodularis Pruritus
Interventions Placebo tablets BID nalbuphine HCl ER tablets 180 mg BID nalbuphine HCl ER tablets 90 mg BID
Updated 13 times since 2017 Last updated: May 19, 2025 Started: Mar 31, 2015 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Nodularis Prurigo and Prurigo, this trial is completed. The trial is conducted by Trevi Therapeutics and has accumulated 13 data snapshots since 2015. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Sep 2020 · 24 months · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Nov 2020 · 31 days · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

13 versions recorded

  1. Jun 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Jun 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2_PHASE3

▶ Show 8 earlier versions

  1. Jan 2021 — Dec 2022 [monthly]

    Completed PHASE2_PHASE3

  2. Nov 2020 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

  3. Oct 2020 — Nov 2020 [monthly]

    Completed PHASE2_PHASE3

  4. Sep 2020 — Oct 2020 [monthly]

    Completed PHASE2_PHASE3

  5. Sep 2018 — Sep 2020 [monthly]

    Completed PHASE2_PHASE3

  6. Jun 2018 — Sep 2018 [monthly]

    Completed PHASE2_PHASE3

  7. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

  8. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Mar 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Trevi Therapeutics
Data source: Trevi Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations